AuntMinnie

JULY 12, 2024

As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. Beyder led a theranostics practice management and logistics track at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in Toronto.

Nuclear Medicine 105

Nuclear Medicine Radiation Oncology Radiopharmaceuticals Radiation 105

Imaging Technology

AUGUST 29, 2023

Administration of the therapeutic dose took place as part of an ongoing Phase I/IIa theranostic clinical trial conducted by Clarity Pharmaceuticals to investigate the safety and efficacy of Cu-67 SARTATE in pediatric patients with high-risk neuroblastoma.

Pharmaceutical 97

Pharmaceutical Radiopharmaceuticals Clinic Medical 97

Imaging Technology

JULY 20, 2023

milla1cf Thu, 07/20/2023 - 20:11 July 20, 2023 — The members of the American Society for Radiation Oncology ( ASTRO ) recently elected three new officers to ASTRO’s Board of Directors, including Sameer Keole , MD, FASTRO , as President-elect; Wendy Woodward , MD, PhD, FASTRO, as Science Council Vice Chair; and Vivek S.

Radiation Oncology 98

Radiation Oncology Radiation Government Community Practice 98

Imaging Technology

JULY 28, 2023

It is the first and only FDA-approved, PSMA-targeted imaging agent developed with proprietary radiohybrid (rh) technology. We believe it further validates the clinical utility of POSLUMA in patients with newly diagnosed or recurrent prostate cancer, and can help expand patient access. POSLUMA was approved by the U.S.

Diagnostic 98

Diagnostic Clinic Radiopharmaceuticals Radiation 98

Imaging Technology

AUGUST 31, 2023

milla1cf Thu, 08/31/2023 - 15:50 August 31, 2023 — NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals, and Curadh MTR Inc. Ac-225 to Curadh for use in its pioneering molecularly targeted radiation (MTR) programs for the treatment of common lethal tumors. “We

Medical 98

Medical Radiopharmaceuticals Pharmaceutical Radiation 98

AuntMinnie

OCTOBER 2, 2024

The following is the list of candidates for the 2024 edition of the Minnies, AuntMinnie.com 's campaign to recognize the best and brightest in medical imaging. Image from Martin W. Image from Denis Le Bihan, PhD, of the NeuroSpin research facility, et al. Image from Richard Carson, PhD, of Yale University, et al.

Digital Imaging and Communications in Medicine 137

Digital Imaging and Communications in Medicine X-ray MRI Hospital 137

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

Imaging Technology

JANUARY 12, 2024

“We are grateful that CMS recognizes the potential of our SCINTIX therapy for patients with all stages of indicated cancers and, with this decision, has addressed provider payment as a barrier to clinical adoption,” continued Powell. Patient treatments also began at several clinical sites in 2023. 1, 2024, to describe SCINTIX therapy.

Radiopharmaceuticals 105

Radiopharmaceuticals Radiation Medicare Clinic 105

Imaging Technology

JULY 5, 2023

Ac-225 is a high energy alpha-emitting radioisotope of increasing interest for clinical studies investigating the use of targeted radiopharmaceutical therapy, which combines select molecules with therapeutic radioisotopes to directly target and deliver therapeutic doses of radiation to destroy cancer cells in patients with serious disease.

Medical 92

Medical Radiopharmaceuticals Pharmaceutical Radiation 92

AuntMinnie

JUNE 20, 2024

F-18 fluorocholine (FCH) PET/CT could be a first-line technique over technetium-99m sestamibi (Tc-99m MIBI) SPECT/CT for imaging parathyroid tumors prior to surgery, according to a study published June 20 in JAMA Otolaryngology-Head & Neck Surgery. No complications occurred. The full study is available here.

Radiopharmaceuticals 105

Radiopharmaceuticals Radiation Imaging Clinic 105

AuntMinnie

JANUARY 11, 2024

RefleXion said while other technologies use anatomical images to guide radiotherapy delivery, Scintix therapy is the only radiotherapy to use emissions from cancer cells. These are created by injecting the patient with a radiopharmaceutical to deliver a radiation dose that targets the cancer itself.

Radiopharmaceuticals 52

Radiopharmaceuticals Medicare Radiation Hospital 52

Imaging Technology

APRIL 2, 2024

announced the acquisition’s close and addition of MIM Software’s imaging analytics and digital workflow solutions as a part of its leading global medical technology, pharmaceutical diagnostics, and digital portfolio. There is also special focus on radiation therapy and Theranostics.

Healthcare 105

Healthcare Healthcare Radiation Oncology Magnetic Resonance Imaging 105

TTG Imaging Solutions

MAY 5, 2023

Enhances TTG’s continued commitment to offer a full spectrum of high-quality and cost-effective service solutions in the cardiology and radiation oncology markets PITTSBURGH, PA (May 5, 2023) – TTG Imaging Solutions, LLC (TTG) announced today the acquisition of Digirad Health, Inc., headquartered in Suwanee, GA. Digirad Health, Inc.

Imaging 52

Imaging Radiopharmaceuticals Radiation Oncology Nuclear Medicine 52

AuntMinnie

MARCH 25, 2024

PET/CT is poised to become a key tool for imaging the coronary arteries – a clinical imaging exam that can reveal early warning signs of fatal conditions when patients present with symptoms of chest pain, experts say. The game-changer could be the pending U.S. approval of new PET radiotracers, such as F-18 flurpiridaz , he said.

Nuclear Medicine 128

Nuclear Medicine Radiopharmaceuticals Disease Radiation 128

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. It is the first and only FDA-approved, PSMA-targeted imaging agent developed with proprietary radiohybrid (rh) technology.

Diagnostic 97

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 97

Imaging Technology

MAY 14, 2024

milla1cf Tue, 05/14/2024 - 12:45 May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on their 40-year history of clinical and research collaboration. This alliance will help UH expand patient access and transform cancer care from discovery to recovery.

Hospital 116

Hospital Magnetic Resonance Imaging Radiopharmaceuticals Disease 116

Imaging Technology

SEPTEMBER 27, 2023

PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. from October 1 to 4, 2023. Gauden , D.Phil., Chief Executive Officer of Blue Earth Diagnostics.

Diagnostic 105

Diagnostic Radiation Oncology Radiation Clinic 105

AuntMinnie

APRIL 4, 2024

A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. Even if some private urology, radiation oncology practices, or radiologist groups are building the ability to perform theranostics, experts are cautious about patient management, radiation safety, and the risk of unnecessary imaging.

Nuclear Medicine 88

Nuclear Medicine Radiation Oncology Nursing Radiation 88

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52

Imaging Technology

AUGUST 23, 2023

SCINTIX therapy is a cutting-edge radiopharmaceutical-directed treatment applicable for early and late-stage cancers that uses the individual biology of each tumor to drive its own treatment. “We founder and CTO of RefleXion. “We founder and CTO of RefleXion.“We

Radiopharmaceuticals 98

Radiopharmaceuticals Disease Radiation Clinic 98

AuntMinnie

JUNE 14, 2024

Extravasations have never been required to be reported, NRC's senior health physicist Cindy Flannery said June 11 during a regulatory session at the Society of Nuclear Medicine and Molecular Imaging's (SNMMI) recent meeting in Toronto. That might do away with diagnostic concerns, Flannery noted.

Nuclear Medicine 52

Nuclear Medicine Radiation Radiopharmaceuticals Medical 52

Imaging Technology

OCTOBER 18, 2023

About Targeted Alpha Therapy Targeted Alpha Therapy is an emerging class of cancer therapeutics, which seeks to deliver alpha radiation directly to the tumor while minimizing radiation exposure to normal tissue. Targeted radiopharmaceuticals are created by linking a therapeutic radioisotope to a targeting molecule (e.g.,

Radiopharmaceuticals 115

Radiopharmaceuticals Pharmaceutical Radiation Medical 115

Imaging Technology

JULY 21, 2023

Several of these presentations detail our successfully completed clinical study that supported our FDA clearance for SCINTIX therapy, while others explore its breakthrough potential in treating multiple moving tumors.” will share their clinical experience with the X1 and how they are preparing for SCINTIX therapy. Chunhui Han , Ph.D.,

Radiopharmaceuticals 98

Radiopharmaceuticals Clinic Radiation Medical 98

Imaging Technology

OCTOBER 5, 2023

Specifically, this sub-group examined the performance of flotufolastat F 18 PET in newly diagnosed, high-risk prostate cancer patients who had negative results with conventional imaging. Kuo, MD, Ph.D. , Departments of Medical Imaging, Medicine, and Biomedical Engineering. Recently approved by the U.S. Gauden, D.Phil.

Diagnose 52

Diagnose Diagnostic Disease Radiation 52

Imaging Technology

JULY 25, 2023

The ubiquitous expression of FAP in cancer-associated fibroblasts across nearly all epithelial-derived cancers paired with the low abundance in normal tissues, makes it a unique target to exploit for tumor imaging for a wide variety of cancers such as breast, pancreatic, lung and stomach cancer.

Radiopharmaceuticals 98

Radiopharmaceuticals Imaging Pharmaceutical Disease 98

AuntMinnie

JUNE 3, 2024

With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., Siegel told AuntMinnie.com. "My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.

Nuclear Medicine 105

Nuclear Medicine Radiopharmaceuticals Radiation Radiation Oncology 105

Imaging Technology

JULY 11, 2023

The ubiquitous expression of FAP in cancer-associated fibroblasts across nearly all epithelial-derived cancers paired with the low abundance in normal tissues, makes it a unique target to exploit for tumor imaging for a wide variety of cancers such as breast, pancreatic, lung and stomach cancer.

Radiopharmaceuticals 75

Radiopharmaceuticals Imaging Pharmaceutical Disease 75

Imaging Technology

JUNE 29, 2023

milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1

Clinic 98

Clinic Nuclear Medicine Radiopharmaceuticals Radiation 98

Imaging Technology

APRIL 3, 2023

produced, non-uranium based Mo-99 for use in diagnostic imaging. Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit.

Medical 98

Medical Radiopharmaceuticals Pharmaceutical Radiation 98

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 PET imaging currently under review by the U.S.

Diagnostic 98

Diagnostic Radiopharmaceuticals Imaging Radiation 98

Imaging Technology

AUGUST 30, 2023

The study was published in the International Journal of Radiation Oncology, Biology, Physics. FLASH is an experimental mode of delivering radiation therapy for cancer that can be delivered to a patient in less than one second and which can be over 100 times faster than conventional radiation therapy.

Radiation Oncology 111

Radiation Oncology Radiation Radiopharmaceuticals Clinic 111